Stabilization of Biopharmaceuticals in Single Crystal Hosts

单晶主体中生物药物的稳定性

• 批准号: 9727492
• 负责人: Bart Kahr
• 金额: $ 47.6万
• 依托单位: University of Washington
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-15 至 2001-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9727492&HistoricalAwards=false
• 关键词: Stabilization; Biopharmaceuticals; Single; Crystal; Hosts

Professor Bart Kahr, of the Department of Chemistry at the University of Washington, is supported by the Organic and Macromolecular Chemistry Program and the Office of Multidisciplinary Activities of the Mathematical and Physical Sciences Directorate through a Grant Opportunities for Academic Liaisons with Industry (GOALI) award for his studies of the stabilization of biopharmaceuticals in single crystal hosts. Through exploration of the host/guest chemistry of single crystals of known biopharmaceuticals and excipients and the single crystal matrix isolation of biopolymers in hydrogen-bonded molecular crystals, Professor Kahr and co-Principal Investigators Jean Chmielewski, of Purdue University, and Jerry Lewis, of Eli Lilly, are developing methods for the stabilization toward light, heat, and moisture of various peptidic pharmaceuticals, including glucagon and human growth hormone. The stability of the mixed crystals and the activity of the biopharmaceuticals upon release from their crystal hosts will be explored through a variety of physical and biological assays. In part due to the emergence of recombinant DNA technologies, a number of biopharmaceutical agents are appearing. These drugs, often comprised of polypeptides (proteins), generally display poorer stability toward ambient conditions of light, temperature, and humidity than do typical small-molecule drugs, and development of methods for their stabilization beyond storage at low temperature, which is not always practically feasible, are required. Through a Grant Opportunities for Academic Liaisons with Industry (GOALI) award, the Organic and Macromolecular Chemistry Program and the Office of Multidisciplinary Activities of the Mathematical and Physical Sciences Directorate support Professor Bart Kahr, of the Department of Chemistry at the University of Washington, for his studies of the inclusion of biopharmaceutical agents within single crystal `hosts.` Professor Kahr's studies are focused on the ability of biopolymers, including human growth hormone, to crystallize within the crystal lattice of various pharmaceutical `excipients` and on the effects of this incorporation on the thermal, light, and moisture stability of these biopolymers.

伦敦大学化学系的巴特·卡尔教授说， 华盛顿，由有机和大分子化学 方案和多学科活动办公室 数学和物理科学理事会通过赠款 机会与产业学术联络（GOALI）奖，他的 生物药物单晶稳定化的研究 hosts. 通过探索单分子的主/客体化学， 已知的生物药物和赋形剂的晶体和单一的 氢键分子中生物聚合物的晶体基质分离 Kahr教授和共同首席研究员Jean Chmielewski 和礼来公司的杰里刘易斯正在开发 本发明提供了用于使各种聚合物对光、热和水分稳定的方法， 肽类药物，包括胰高血糖素和人生长激素。 混合晶体的稳定性和活性 将探索从其晶体宿主释放的生物药物 通过各种物理和生物分析。 部分由于重组DNA技术的出现， 生物药剂正在出现。 这些药物通常由 多肽（蛋白质），通常表现出较差的稳定性， 环境条件的光，温度和湿度比典型的 小分子药物及其稳定化方法的开发 除了低温储存之外，这并不总是实际的 可行的，是必需的。 通过奖学金机会， 工业联络（GOALI）奖，有机和高分子 化学计划和多学科活动办公室 数学和物理科学理事会支持教授巴特 卡尔，化学系在华盛顿大学，为 他的研究包括生物药剂在单一的 水晶“主机。” 卡尔教授的研究重点是 生物聚合物，包括人类生长激素，在 各种药物“赋形剂”的晶格和对 这种结合对热，光，和水分稳定性， 这些生物聚合物。